From the 9/20/2018 PR....In coming weeks, the Comp

From the 9/20/2018 PR....In coming weeks, the Company plans to submit a request for an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) to discuss appropriate next steps in the development of Brilacidin for the treatment of Oral Mucositis (OM), which has already been granted Fast Track designation. A Breakthrough Therapy Designation application is currently under review with the FDA.

Thus 9/20/2018 has to be the latest..